Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GMABNASDAQ:ITCINASDAQ:RYTMNASDAQ:SMMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMABGenmab A/S$20.44-1.4%$21.01$17.24▼$28.56$13.30B0.941.22 million shs1.31 million shsITCIIntra-Cellular Therapies$131.87$131.87$67.68▼$131.98$14.05B0.691.52 million shsN/ARYTMRhythm Pharmaceuticals$66.92+2.3%$62.77$40.46▼$69.89$4.16B2.26555,926 shs963,104 shsSMMTSummit Therapeutics$22.62+6.7%$22.97$6.78▼$36.91$15.74B-1.013.65 million shs3.81 million shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMABGenmab A/S-1.45%-0.39%-6.11%+6.24%-17.91%ITCIIntra-Cellular Therapies0.00%0.00%0.00%0.00%+92.40%RYTMRhythm Pharmaceuticals+2.26%+7.43%+5.12%+34.32%+58.05%SMMTSummit Therapeutics+6.70%+6.35%+27.58%+19.62%+200.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGMABGenmab A/S3.8921 of 5 stars3.35.00.00.02.20.03.1ITCIIntra-Cellular Therapies0.9104 of 5 stars1.10.00.04.50.01.70.6RYTMRhythm Pharmaceuticals3.9005 of 5 stars3.52.00.04.31.90.80.6SMMTSummit Therapeutics2.6319 of 5 stars4.41.00.00.02.61.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGMABGenmab A/S 2.67Moderate Buy$37.6083.95% UpsideITCIIntra-Cellular Therapies 2.17Hold$109.70-16.81% DownsideRYTMRhythm Pharmaceuticals 3.00Buy$77.3115.52% UpsideSMMTSummit Therapeutics 2.79Moderate Buy$34.6753.26% UpsideCurrent Analyst Ratings BreakdownLatest RYTM, SMMT, ITCI, and GMAB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2025SMMTSummit TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$44.007/1/2025SMMTSummit TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.006/26/2025RYTMRhythm PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$84.006/11/2025SMMTSummit TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell6/11/2025SMMTSummit TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageUnderperform$12.006/2/2025SMMTSummit TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$40.005/29/2025RYTMRhythm PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$78.00 ➝ $94.005/8/2025SMMTSummit TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/7/2025RYTMRhythm PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$66.00 ➝ $72.005/2/2025SMMTSummit TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$37.00 ➝ $41.004/28/2025SMMTSummit TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$44.00(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGMABGenmab A/S$3.12B4.20$1.49 per share13.68$8.04 per share2.54ITCIIntra-Cellular Therapies$680.50M20.64N/AN/A$6.15 per share21.44RYTMRhythm Pharmaceuticals$130.13M32.72N/AN/A$0.35 per share191.20SMMTSummit Therapeutics$700K23,998.85N/AN/A$0.53 per share42.68Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGMABGenmab A/S$1.14B$1.7611.6111.486.8435.11%18.08%14.52%8/14/2025 (Estimated)ITCIIntra-Cellular Therapies-$139.67M-$0.73N/A694.05N/A-14.07%-9.93%-8.38%N/ARYTMRhythm Pharmaceuticals-$260.60M-$2.81N/AN/AN/A-123.26%-739.62%-44.27%8/5/2025 (Estimated)SMMTSummit Therapeutics-$221.32M-$0.34N/AN/AN/AN/A-62.87%-51.61%8/5/2025 (Estimated)Latest RYTM, SMMT, ITCI, and GMAB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025GMABGenmab A/S$0.23$0.31+$0.08$0.31$5.17 billion$715.00 million5/7/2025Q1 2025RYTMRhythm Pharmaceuticals-$0.69-$0.81-$0.12-$0.81$40.43 million$37.72 million5/1/2025Q1 2025SMMTSummit Therapeutics-$0.10-$0.09+$0.01-$0.09N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGMABGenmab A/SN/AN/AN/AN/AN/AITCIIntra-Cellular TherapiesN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ASMMTSummit TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGMABGenmab A/SN/A5.345.32ITCIIntra-Cellular TherapiesN/A7.667.51RYTMRhythm PharmaceuticalsN/A3.303.13SMMTSummit TherapeuticsN/A10.6310.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGMABGenmab A/S7.07%ITCIIntra-Cellular Therapies92.33%RYTMRhythm PharmaceuticalsN/ASMMTSummit Therapeutics4.61%Insider OwnershipCompanyInsider OwnershipGMABGenmab A/S1.54%ITCIIntra-Cellular Therapies2.60%RYTMRhythm Pharmaceuticals6.10%SMMTSummit Therapeutics84.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGMABGenmab A/S2,682641.22 million631.35 millionOptionableITCIIntra-Cellular Therapies560106.52 million103.56 millionOptionableRYTMRhythm Pharmaceuticals14063.62 million59.74 millionOptionableSMMTSummit Therapeutics110742.67 million112.14 millionOptionableRYTM, SMMT, ITCI, and GMAB HeadlinesRecent News About These CompaniesSummit Therapeutics (NASDAQ:SMMT) Coverage Initiated at UBS Group4 hours ago | americanbankingnews.comWall Street Analysts Believe Summit Therapeutics (SMMT) Could Rally 63.02%: Here's is How to TradeJuly 2 at 10:56 AM | zacks.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTJuly 2 at 10:00 AM | prnewswire.comSummit Therapeutics PLC (NASDAQ:SMMT) Receives $35.09 Consensus PT from BrokeragesJuly 2 at 3:17 AM | americanbankingnews.comSummit Therapeutics (NASDAQ:SMMT) Earns Buy Rating from HC WainwrightJuly 2 at 2:29 AM | americanbankingnews.comHC Wainwright Reiterates Buy Rating for Summit Therapeutics (NASDAQ:SMMT)July 1 at 8:40 AM | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Coverage Initiated by Analysts at UBS GroupJuly 1 at 8:26 AM | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Rating Increased to Hold at Wall Street ZenJune 30 at 2:51 AM | americanbankingnews.comSummit Therapeutics PLC (NASDAQ:SMMT) Stock Position Lifted by Sovran Advisors LLCJune 29, 2025 | marketbeat.comLisanti Capital Growth LLC Takes Position in Summit Therapeutics PLC (NASDAQ:SMMT)June 29, 2025 | marketbeat.comWall Street Zen Upgrades Summit Therapeutics (NASDAQ:SMMT) to "Hold"June 29, 2025 | marketbeat.comSummit Therapeutics PLC (NASDAQ:SMMT) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJune 29, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTJune 27, 2025 | prnewswire.comSummit Therapeutics Breaks Above 200-Day Moving Average - Bullish for SMMT - NasdaqJune 26, 2025 | nasdaq.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTJune 23, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTJune 22, 2025 | prnewswire.comWorld Equity Group Inc. Sells 14,062 Shares of Summit Therapeutics PLC (NASDAQ:SMMT)June 22, 2025 | marketbeat.comGAMMA Investing LLC Purchases 15,331 Shares of Summit Therapeutics PLC (NASDAQ:SMMT)June 21, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Downgraded to "Sell" Rating by Wall Street ZenJune 21, 2025 | marketbeat.comSummit Therapeutics PLC (NASDAQ:SMMT) Shares Sold by Five Pine Wealth ManagementJune 20, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTJune 18, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRYTM, SMMT, ITCI, and GMAB Company DescriptionsGenmab A/S NASDAQ:GMAB$20.44 -0.30 (-1.45%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$20.40 -0.04 (-0.19%) As of 06:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Intra-Cellular Therapies NASDAQ:ITCI$131.87 0.00 (0.00%) As of 04/2/2025Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.Rhythm Pharmaceuticals NASDAQ:RYTM$66.92 +1.48 (+2.26%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$68.41 +1.49 (+2.23%) As of 07/2/2025 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Summit Therapeutics NASDAQ:SMMT$22.62 +1.42 (+6.70%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$23.31 +0.69 (+3.05%) As of 06:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Jefferies Raises Broadcom Price Target to $315: 19% Upside Ahead Dan Ives’ Bold $5 Trillion Forecast for Microsoft Stock 3 Utility Stocks That Combine Income and Stability 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
